iPad games effective against amblyopia

Article

A home-based treatment of amblyopia that incorporated an iPad quickly resulted in improved visual acuity (VA) in the children in whom it was tested, and VA remained stable for at least 3 months after the treatment ended, according to research published online.

A home-based treatment of amblyopia that incorporated an iPad quickly resulted in improved visual acuity (VA) in the children in whom it was tested, and VA remained stable for at least 3 months after the treatment ended, according to research published online by Eye.

The binocular treatment is promising, according to the Texas researchers, because monocular treatment does not always lead to 6/6 vision, and patients often see the return of amblyopia. "In addition to the efficacy and durability of this binocular iPad treatment, it is fun and engaging and results in better compliance than patching, at the same time imposes little risk for adverse psychosocial effects," the authors say.

In the study, children aged 4 to 12 years played either sham games or binocular games on an iPad for 4 hours a week for 4 weeks while wearing anaglyphic glasses. Children assigned to binocular games could choose to play for an additional 4 weeks.

The sham group had 25 children, and the binocular group had 50. Approximately half of the children in each group also wore patching at a different time of day than when they were playing games.

Researchers measured best-corrected VA, suppression and stereoacuity at baseline, at the 4- and 8-week outcome visits, and 3 months after treatment ended. They found that, in the binocular group, mean VA went from 0.47±0.03 logMAR at baseline to 0.39±0.03 logMAR at 4 weeks. No significant change was seen in the sham group.

Patching did not change the effect of the binocular games on VA in the children, nor did an additional 4 weeks of treatment in those children playing the binocular games result in greater improvement in VA. Median stereoacuity remained unchanged in both groups.

For full details of the study click

here

.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.